FGFR2 and intrahepatic cholangiocarcinoma: A noteworthy finding is that 90% of patients diagnosed with ICC and having KRAS mutations also showed positive findings for FGFR2 fusions, suggesting a potential collaborative role in promoting the progression of malignant tumors [65].